Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASC30 Tablets in Participants With Obesity

NCT06680440 is registered in ClinicalTrials.gov with Ascletis Pharma (China) Co., Limited as lead sponsor.

NCT NCT06680440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06680440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASC30 Tablets in Participants With Obesity
Lead sponsor
Ascletis Pharma (China) Co., Limited
Phase
Phase 1
Overall status
Completed
Start date
August 26, 2024
Completion date
April 3, 2025
Enrollment
72 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

weight management